These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 26860539)

  • 1. Future directions in bladder cancer immunotherapy: towards adaptive immunity.
    Smith SG; Zaharoff DA
    Immunotherapy; 2016; 8(3):351-65. PubMed ID: 26860539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.
    Begnini KR; Buss JH; Collares T; Seixas FK
    Appl Microbiol Biotechnol; 2015 May; 99(9):3741-54. PubMed ID: 25794874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
    Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
    APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17 production by γδ T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guérin treatment against bladder cancer.
    Takeuchi A; Dejima T; Yamada H; Shibata K; Nakamura R; Eto M; Nakatani T; Naito S; Yoshikai Y
    Eur J Immunol; 2011 Jan; 41(1):246-51. PubMed ID: 21182095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.
    Ayari C; Besançon M; Bergeron A; LaRue H; Bussières V; Fradet Y
    Cancer Immunol Immunother; 2016 Feb; 65(2):223-34. PubMed ID: 26759009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are gamma delta T lymphocytes involved in intravesical bacillus Calmette-Guerin immunotherapy of bladder cancer?
    Alexandroff AB; Black J; Bollina P; Esuvaranathan K; James K
    Biochem Soc Trans; 1997 May; 25(2):363S. PubMed ID: 9191408
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.
    Takeuchi A; Eto M; Tatsugami K; Shiota M; Yamada H; Kamiryo Y; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Takahashi R; Yokomizo A; Ohara N; Yoshikai Y
    Int Immunopharmacol; 2016 Jun; 35():327-331. PubMed ID: 27093372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
    Zichi C; Tucci M; Leone G; Buttigliero C; Vignani F; Pignataro D; Scagliotti GV; Di Maio M
    Biomed Res Int; 2017; 2017():5618174. PubMed ID: 28680882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-10R1 monoclonal antibody enhances bacillus Calmette-Guérin induced T-helper type 1 immune responses and antitumor immunity in a mouse orthotopic model of bladder cancer.
    Bockholt NA; Knudson MJ; Henning JR; Maymí JL; Weady P; Smith GJ; Eisenbraun MD; Fraser JD; O'Donnell MA; Luo Y
    J Urol; 2012 Jun; 187(6):2228-35. PubMed ID: 22503050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.
    Newton MR; Askeland EJ; Andresen ED; Chehval VA; Wang X; Askeland RW; O'Donnell MA; Luo Y
    Clin Exp Immunol; 2014 Jul; 177(1):261-8. PubMed ID: 24593764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late effects of intravesical bacillus Calmette-Guérin immunotherapy on bladder mucosa infiltrating lymphocytes: an immunohistochemical study.
    Boccafoschi C; Montefiore F; Pavesi M; Pastormerlo M; Betta PG
    Eur Urol; 1995; 27(4):334-8. PubMed ID: 7544736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment.
    Zeng S; Xing S; Zhang Y; Wang H; Liu Q
    J Zhejiang Univ Sci B; 2024 Jul; 25(7):557-567. PubMed ID: 39011676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers.
    Kim YJ; Ha YS; Kim SK; Yoon HY; Lym MS; Kim MJ; Moon SK; Choi YH; Kim WJ
    Clin Cancer Res; 2010 Apr; 16(7):2131-7. PubMed ID: 20233890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.
    Kresowik TP; Griffith TS
    Immunotherapy; 2009 Mar; 1(2):281-8. PubMed ID: 20046960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
    Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
    J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
    Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.